Christopher James Stevens - 04 Aug 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Operating Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Christopher James Stevens
Issuer symbol
RCKT
Transactions as of
04 Aug 2025
Net transactions value
$0
Form type
4
Filing time
06 Aug 2025, 16:11:04 UTC
Previous filing
04 Aug 2025
Next filing
13 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stevens Christopher James Chief Operating Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY /s/ Martin Wilson, as attorney-in-fact for Christopher James Stevens 06 Aug 2025 0002079768

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Award $0 +407,166 $0.000000 407,166 04 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Stock Option (Right to Buy) Award $0 +554,071 $0.000000 554,071 04 Aug 2025 Common Stock 554,071 $3.07 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on August 4, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.
F2 This option represents a right to purchase a total of 554,071 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on August 4, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.